Guangzhou Innogen Pharmaceutical (HKG:2591) said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice (GMP) certification from Brazil's health regulator, ANVISA.
The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.